Medicilon and Hailu Biotech of Yangtze River Pharmaceutical Group Forge Strategic Cooperation to Accelerate New Drug R&D and Global Outreach
On March 30, Medicilon held a strategic cooperation signing ceremony with Suzhou Hailu Biotech, a wholly-owned subsidiary of Yangtze River Pharmaceutical Group. The collaboration will focus on deepening synergy in preclinical new drug R&D, project introduction, and global market expansion, with the goal of jointly building an efficient, open, and international R&D ecosystem spanning from source […]
Oligonucleotide Therapeutics: Conjugation Chemistry & In Vitro Activity Assessment
April 8, 2026
8:00-9:00 PM ET (5:00–6:00 PM PT)
BIO-Europe Spring 2026
March 23, 2026,
to March 25, 2026
【Case Study】New Approach Methods NAMs
Learn more about our NAMs platform 2D vs 3D hepatocyte model for acetaminophen-induced toxicity A 2D HepG2 culture and 3D HepG2 spheroid system can be used to evaluate acetaminophen-induced toxicity with image-based analysis and viability readouts, illustrating how 3D systems can support longer-term, repetitive exposure designs. Cytokine Release Assay (CRA) for immune activation risk Medicilon […]
Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche
Recently, MediLink Therapeutics entered into a new exclusive license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pharmaceutical giant, for YL201, an antibody-drug conjugate (ADC) targeting B7H3.This landmark deal, featuring an upfront payment and near-term milestone payments exceeding USD 570 million, not only serves as a strong recognition of the substantial clinical value and […]
AACR 2026
Friday, April 17, 2026,
to Wednesday, April 25, 2026
【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
Learn more about our CMC Capability Route, Solid-State, and Impurity Optimization (Small-Molecule API) Program Type: Small-molecule APICMC Focus: Route optimization, solid-state control, impurity management Overview In a separate small-molecule program, Medicilon re-engineered the API synthetic route and solid form strategy to significantly improve manufacturability, safety, and analytical control. The work integrated process chemistry, solid-state science, […]
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Learn more about our CMC Capability IND Completion in 12 Months (Small-Molecule NCE) Program Type: Small-molecule New Chemical Entity (NCE)Scope: End-to-end CMC (API process development, analytics, GMP manufacturing, regulatory documentation)Outcome: IND approval achieved ~12 months from contract signing Project Overview Medicilon supported a small-molecule NCE program with fully integrated CMC services, enabling IND approval within […]
DDC 2026
Monday, April 14, 2026,
to Thursday, April 16, 2026
SOT 2026
Sunday, March 22, 2026,
to Wednesday, March 25, 2026
